Examining the relationship between reproductive empowerment and contraceptive self-injection: Tackling the endogeneity problem
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0319330 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Megan M Lydon und 6 weiteren Autor:innen. Beteiligte Einrichtung: FHI 360, Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: Empowerment, Medroxyprogesterone Acetate, Contraceptive Agents, Female, Self Care. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Investment Fund Foundation.
Abstract (Originalsprache)
Background
Self-care interventions, including contraceptive self-injectables such as subcutaneous depot medroxyprogesterone acetate (DMPA-SC), are hypothesized to be empowering to users. It is also believed that those who are empowered are more likely to use self-care. Though critical for ensuring equity of these interventions, evidence for the relationship between empowerment and contraceptive self-care is scant. However, studying this relationship is challenging. In addition to the potential reversed causality between these two constructs, empowerment is determined by similar factors as the motivation for using self-care, contributing to an endogeneity problem. If not addressed, endogeneity can lead to incorrect causal assertions.
Methods
Using data from a study of 400 women in Addis Ababa, Ethiopia who opted to self-inject DMPA-SC, we assessed the directionality between the two constructs. First, we assessed the change in empowerment after participants’ first self-injection. Second, we assessed the effect of empowerment on potential future use of self-injection. To address potential endogeneity, we identified instrumental variables of empowerment and then applied a two-stage regression approach to predict desire to continue self-injecting at follow-up with an instrument for empowerment, controlling for other variables.
Results
Empowerment scores among the 343 women who were followed-up were high and did not significantly change from baseline to endline. Most women (78%) wanted to continue self-injecting. The following variables were identified and used as instruments: religion, employment status and post-secondary school attendance. The final model did not identify a significant relationship between desire to continue self-injecting and empowerment. The test of exogeneity was marginally significant (p = 0.08).
Conclusions
We did not find evidence of a significant relationship between reproductive empowerment and desire to continue self-injecting. Though there are limitations to this secondary data analysis, we recommend future research investigate this relationship using the methodology demonstrated to address endogeneity inherent in answering this critical question about self-care interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- FHI 360, Durham, North Carolina, United States of America.
- PSI, Addis Ababa, Ethiopia.
ORCID-Profile: Megan M Lydon, Holly M Burke
Förderung
- Children's Investment Fund Foundation
Zitieren
APA
Lydon, M. M., Burke, H. M., Anfinson, K. M., Mulugeta, T., Anteneh, A., Teklu, T., & Chen, M. (2025). Examining the relationship between reproductive empowerment and contraceptive self-injection: Tackling the endogeneity problem. PLOS ONE. https://doi.org/10.1371/journal.pone.0319330
Vancouver
Lydon MM, Burke HM, Anfinson KM, Mulugeta T, Anteneh A, Teklu T, et al. Examining the relationship between reproductive empowerment and contraceptive self-injection: Tackling the endogeneity problem. PLOS ONE. 2025. doi:10.1371/journal.pone.0319330
BibTeX
@article{Lydon2025,
author = {Lydon, Megan M and Burke, Holly M and Anfinson, Katherine M and Mulugeta, Tihut and Anteneh, Aderaw and Teklu, Teferi and Chen, Mario},
title = {Examining the relationship between reproductive empowerment and contraceptive self-injection: Tackling the endogeneity problem},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0319330}
}
EUVIMED